Plus Therapeutics Inc (NASDAQ:PSTV)’s traded shares stood at 2.34 million during the last session, with the company’s beta value hitting 0.95. At the close of trading, the stock’s price was $0.51, to imply a decrease of -8.44% or -$0.05 in intraday trading. The PSTV share’s 52-week high remains $2.67, putting it -423.53% down since that peak but still an impressive 52.94% since price per share fell to its 52-week low of $0.24. The company has a valuation of $3.01M, with an average of 51.01 million shares in intraday trading volume over the past 10 days and average of 8.77 million shares over the past 3 months.
Plus Therapeutics Inc (NASDAQ:PSTV) trade information
After registering a -8.44% downside in the last session, Plus Therapeutics Inc (PSTV) has traded red over the past five days. The 5-day price performance for the stock is -57.77%, and -56.69% over 30 days. With these gigs, the year-to-date price performance is -55.57%. Short interest in Plus Therapeutics Inc (NASDAQ:PSTV) saw shorts transact 0.14 million shares and set a 1.23 days time to cover.
Plus Therapeutics Inc (PSTV) estimates and forecasts
The rating firms project that company’s revenue will grow 12.52% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 1.19M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 1.49M.Earnings reports from the last fiscal year show that sales brought in 1.31M and 1.68M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -9.18% before dropping -11.30% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 68.20% for the past 5-year period. While 2025 is set for a 57.50% return in earnings, projections for the next 5 years are at 33.80% annually.
PSTV Dividends
Plus Therapeutics Inc has its next earnings report out on 2024-Nov-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Plus Therapeutics Inc (NASDAQ:PSTV)’s Major holders
Plus Therapeutics Inc insiders hold 2.34% of total outstanding shares, with institutional holders owning 11.50% of the shares at 11.78% float percentage. In total, 11.50% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Plus Therapeutics Inc (PSTV) shares. Going by data provided on Dec 31, 2024, Fidelity Extended Market Index Fund holds roughly 34.96 shares. This is just over 0.30% of the total shares, with a market valuation of $17862.0. Data from the same date shows that the other fund manager holds a little less at 32.54, or 0.28% of the shares, all valued at about 16628.0.
